All Clinical Trials

A listing of 23128 clinical trials actively recruiting volunteers for paid trials and research studies in various therapeutic areas.

Home

All Trials

Show Filters

Match to Clinical Trials

Access to cutting-edge treatments

Latest clinical trials

Find trials in your area

Start Matching

Filter by Age

Featured Trial

Paid Clinical Studies Nationwide

Recruiting

Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.

Conditions:

Healthy

Healthy Volunteer Study

Learn More

* Compensation for time may be available

Featured Trial

Chronic Cough Study

Recruiting

Are you tired of living with chronic cough? The ASPIRE Study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough. You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you.

Conditions:

Chronic Cough

Refractory or Unexplained Chronic Cough

Cough

Asthma

Allergic Asthma

Learn More

Featured Trial

Type 2 Diabetes Clinical Trial

Recruiting

Can changing your breakfast improve your type 2 diabetes? If you have an HbA1C of 7.0% or higher, you are invited to participate in an online study at the University of Michigan.

Conditions:

Type 2 Diabetes

Diabetes Mellitus Type 2 in Obese

Diabetes Type Two

Type 2 Diabetes Mellitus

Diabete Type 2

Learn More

Featured Trial

Crohn's Disease Clinical Study

Recruiting

Help us study a potential new way to treat Crohn's disease. We are seeking adults living with Crohn's disease to join our latest clinical trial to help us learn more. Eligible participants will receive study-related treatment, assessments, and care at no cost. You will also receive reimbursement for travel while participating. Health insurance is not required to take part.

Conditions:

Crohn's Disease

Crohn Disease

Crohns Disease

Crohn's Disease (CD)

Crohn Colitis

Learn More

Featured Offer

Lose Weight with GLP-1 Medications

Recruiting

Policy Lab has partnered with CareGLP to offer trusted access to GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.

GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.

As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.

Conditions:

Overweight

Overweight and Obesity

Obesity

Weight Loss

Morbid Obesity

Learn More

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

NCT02610426

Recruiting

This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with congestive heart failure receiving therapy for breast cancer. Studying samples of germline DNA in the laboratory from patients with congestive heart failure receiving therapy for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to congestive heart failure.

Gender:

ALL

Ages:

All

Trial Updated:

12/24/2024

Locations: Eastern Cooperative Oncology Group, Boston, Massachusetts

Conditions: Breast Carcinoma

Learn More ›

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Peripheral Neuropathy Receiving Paclitaxel for Breast Cancer

NCT02610439

Recruiting

This research trial studies whole exome sequencing in finding causative variants in germline deoxyribonucleic acid (DNA) samples from patients with peripheral neuropathy receiving chemotherapy for breast cancer. Studying samples of germline DNA in the laboratory from patients with peripheral neuropathy receiving paclitaxel for breast cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to peripheral neuropathy.

Gender:

ALL

Ages:

All

Trial Updated:

12/24/2024

Locations: Eastern Cooperative Oncology Group, Boston, Massachusetts

Conditions: Breast Carcinoma, Neuropathy

Learn More ›

Product Performance Report: Evaluate Long-term Reliability & Performance of Medtronic Marketed Cardiac Therapy Products

NCT00271180

Recruiting

The main purpose of the Product Performance Report (formerly referred to as System Longevity Study) is to evaluate long-term performance of Medtronic market-released cardiac rhythm products by analyzing product survival probabilities.

Gender:

ALL

Ages:

All

Trial Updated:

12/23/2024

Locations: Not set, Birmingham, Alabama +308 locations

Not set, Birmingham, Alabama

Not set, Anchorage, Alaska

Not set, Chandler, Arizona

Not set, Jonesboro, Arkansas

Not set, Little Rock, Arkansas

Not set, Bakersfield, California

Not set, Chula Vista, California

Not set, La Jolla, California

Not set, Los Angeles, California

Not set, Palm Springs, California

Not set, Rancho Mirage, California

Not set, Redwood City, California

Not set, Salinas, California

Not set, San Diego, California

Not set, Stanford, California

Not set, Torrance, California

Not set, Van Nuys, California

Not set, Ventura, California

Not set, Centennial, Colorado

Not set, Colorado Springs, Colorado

Not set, Denver, Colorado

Not set, Lakewood, Colorado

Not set, Hartford, Connecticut

Not set, New Haven, Connecticut

Not set, Washington, District of Columbia

Not set, Bradenton, Florida

Not set, Clearwater, Florida

Not set, Hollywood, Florida

Not set, Jacksonville, Florida

Not set, Panama City, Florida

Not set, Safety Harbor, Florida

Not set, Sarasota, Florida

Not set, Atlanta, Georgia

Not set, Marietta, Georgia

Not set, Evansville, Indiana

Not set, Indianapolis, Indiana

Not set, West Des Moines, Iowa

Not set, Kansas City, Kansas

Not set, Edgewood, Kentucky

Not set, Louisville, Kentucky

Not set, Baton Rouge, Louisiana

Not set, Shreveport, Louisiana

Not set, Baltimore, Maryland

Not set, Bethesda, Maryland

Not set, Clinton, Maryland

Not set, Hyattsville, Maryland

Not set, Salisbury, Maryland

Not set, Silver Spring, Maryland

Not set, Takoma Park, Maryland

Not set, Boston, Massachusetts

Not set, Lansing, Michigan

Not set, Marquette, Michigan

Not set, Ypsilanti, Michigan

Not set, Coon Rapids, Minnesota

Not set, Minneapolis, Minnesota

Not set, Robbinsdale, Minnesota

Not set, Rochester, Minnesota

Not set, Saint Cloud, Minnesota

Not set, Saint Paul, Minnesota

Not set, Hattiesburg, Mississippi

Not set, Columbia, Missouri

Not set, Kansas City, Missouri

Not set, Saint Louis, Missouri

Not set, Omaha, Nebraska

Not set, Marlton, New Jersey

Not set, Morristown, New Jersey

Not set, New Brunswick, New Jersey

Not set, Ocean City, New Jersey

Not set, Ridgewood, New Jersey

Not set, Albuquerque, New Mexico

Not set, Huntington, New York

Not set, Manhasset, New York

Not set, New York, New York

Not set, Poughkeepsie, New York

Not set, Utica, New York

Not set, Durham, North Carolina

Not set, Raleigh, North Carolina

Not set, Akron, Ohio

Not set, Cincinnati, Ohio

Not set, Cleveland, Ohio

Not set, Columbus, Ohio

Not set, Toledo, Ohio

Not set, Oklahoma City, Oklahoma

Not set, Portland, Oregon

Not set, Allentown, Pennsylvania

Not set, Bethlehem, Pennsylvania

Not set, Danville, Pennsylvania

Not set, Erie, Pennsylvania

Not set, Lancaster, Pennsylvania

Not set, Philadelphia, Pennsylvania

Not set, Pittsburgh, Pennsylvania

Not set, Wilkes-Barre, Pennsylvania

Not set, Columbia, South Carolina

Not set, Germantown, Tennessee

Not set, Nashville, Tennessee

Not set, Austin, Texas

Not set, Dallas, Texas

Not set, Fort Worth, Texas

Not set, Houston, Texas

Not set, Plano, Texas

Not set, The Woodlands, Texas

Not set, Tyler, Texas

Not set, Burlington, Vermont

Not set, Charlottesville, Virginia

Not set, Olympia, Washington

Not set, Spokane, Washington

Not set, Madison, Wisconsin

Not set, Milwaukee, Wisconsin

Not set, Chermside, Not set

Not set, Douglas, Not set

Not set, Murdoch, Not set

Not set, Southport, Not set

Not set, Graz, Not set

Not set, Innsbruck, Not set

Not set, Linz, Not set

Not set, Wien, Not set

Not set, Brugge, Not set

Not set, Brussel, Not set

Not set, Edegem, Not set

Not set, Leuven, Not set

Not set, Liège, Not set

Not set, Yvoir, Not set

Not set, Calgary, Not set

Not set, Kingston, Not set

Not set, Montreal, Not set

Not set, Québec, Not set

Not set, Beijing, Not set

Not set, Changsha, Not set

Not set, Dalian, Not set

Not set, Fuzhou, Not set

Not set, Guangzhou, Not set

Not set, Hangzhou, Not set

Not set, Harbin, Not set

Not set, Kunming, Not set

Not set, Nanchang, Not set

Not set, Shanghai, Not set

Not set, Shantou, Not set

Not set, Suzhou, Not set

Not set, Taiyuan, Not set

Not set, Tianjin, Not set

Not set, Praha, Not set

Not set, Copenhagen, Not set

Not set, Hellerup, Not set

Not set, Hillerød, Not set

Not set, Odense, Not set

Not set, Århus, Not set

Not set, Helsinki, Not set

Not set, Avignon, Not set

Not set, Bayonne, Not set

Not set, Brest, Not set

Not set, Caen, Not set

Not set, Chambray-lès-Tours, Not set

Not set, Clermont-Ferrand, Not set

Not set, Dijon, Not set

Not set, La Rochelle, Not set

Not set, La Tronche, Not set

Not set, Lille, Not set

Not set, Montpellier, Not set

Not set, Nantes, Not set

Not set, Neuilly-sur-Seine, Not set

Not set, Paris, Not set

Not set, Pessac, Not set

Not set, Pringy, Not set

Not set, Rennes, Not set

Not set, Saint-Priest-en-Jarez, Not set

Not set, Strasbourg, Not set

Not set, Toulouse, Not set

Not set, Vandoeuvre les Nancy, Not set

Not set, Villeurbanne, Not set

Not set, Aachen, Not set

Not set, Bad Oeynhausen, Not set

Not set, Bremen, Not set

Not set, Dresden, Not set

Not set, Düsseldorf, Not set

Not set, Essen, Not set

Not set, Hamburg, Not set

Not set, Hannover, Not set

Not set, Heidelberg, Not set

Not set, Homburg, Not set

Not set, Jena, Not set

Not set, Köln, Not set

Not set, München, Not set

Not set, Münster, Not set

Not set, Tübingen, Not set

Not set, Ulm, Not set

Not set, Athens, Not set

Not set, Marousi, Not set

Not set, Thessaloníki, Not set

Not set, Hong Kong, Not set

Not set, Budapest, Not set

Not set, Reykjavik, Not set

Not set, Bangalore, Not set

Not set, Gurgaon, Not set

Not set, New Delhi, Not set

Not set, Ashkelon, Not set

Not set, Be'er Sheva, Not set

Not set, Jerusalem, Not set

Not set, Ramat Gan, Not set

Not set, Ancona, Not set

Not set, Bari, Not set

Not set, Bologna, Not set

Not set, Brescia, Not set

Not set, Castrovillari, Not set

Not set, Cotignola, Not set

Not set, Lecce, Not set

Not set, Milano, Not set

Not set, Monza, Not set

Not set, Pisa, Not set

Not set, Taranto, Not set

Not set, Udine, Not set

Not set, Ageo, Not set

Not set, Gifu, Not set

Not set, Hidaka, Not set

Not set, Hiroshima City, Not set

Not set, Kagoshima, Not set

Not set, Kamakura, Not set

Not set, Kawasaki, Not set

Not set, Kitakyushu, Not set

Not set, Koshigaya, Not set

Not set, Kyoto, Not set

Not set, Mitaka, Not set

Not set, Nagoya, Not set

Not set, Niigata, Not set

Not set, Okayama, Not set

Not set, Sapporo, Not set

Not set, Shinagawa-Ku, Not set

Not set, Shizuoka, Not set

Not set, Suita, Not set

Not set, Tokyo, Not set

Not set, Toyoake, Not set

Not set, Urasoe, Not set

Not set, Yamagata, Not set

Not set, Yokohama, Not set

Not set, Ōsaka-sayama, Not set

Not set, Cheongju-si, Not set

Not set, Daejeon, Not set

Not set, Gyeonggi-do, Not set

Not set, Seoul, Not set

Not set, Suwon-si, Not set

Not set, Hadiya, Not set

Not set, Kuwait, Not set

Not set, Kuala Lumpur, Not set

Not set, Amsterdam, Not set

Not set, Breda, Not set

Not set, Den Haag, Not set

Not set, Eindhoven, Not set

Not set, Enschede, Not set

Not set, Groningen, Not set

Not set, Leiden, Not set

Not set, Maastricht, Not set

Not set, Nieuwegein, Not set

Not set, Rotterdam, Not set

Not set, Christchurch, Not set

Not set, Bergen, Not set

Not set, Oslo, Not set

Not set, Trondheim, Not set

Not set, Poznań, Not set

Not set, Warsaw, Not set

Not set, Zabrze, Not set

Not set, Carnaxide, Not set

Not set, Creixomil, Not set

Not set, Lisboa, Not set

Not set, Porto, Not set

Not set, Santarém, Not set

Not set, Jeddah, Not set

Not set, Riyadh, Not set

Not set, Belgrade, Not set

Not set, Bratislava, Not set

Not set, Košice, Not set

Not set, Ljubljana, Not set

Not set, A Coruña, Not set

Not set, Barcelona, Not set

Not set, Córdoba, Not set

Not set, Girona, Not set

Not set, Granada, Not set

Not set, Madrid, Not set

Not set, Palma De Mallorca, Not set

Not set, Salamanca, Not set

Not set, Santa Cruz De Tenerife, Not set

Not set, Santiago de Compostela, Not set

Not set, Toledo, Not set

Not set, Valencia, Not set

Not set, Valladolid, Not set

Not set, Vitoria-Gasteiz, Not set

Not set, Göteborg, Not set

Not set, Lund, Not set

Not set, Skövde, Not set

Not set, Uppsala, Not set

Not set, Basel, Not set

Not set, Bern, Not set

Not set, Fribourg, Not set

Not set, Geneva, Not set

Not set, Lausanne, Not set

Not set, Lugano, Not set

Not set, Zürich, Not set

Not set, Birmingham, Not set

Not set, Blackpool, Not set

Not set, Bristol, Not set

Not set, Leeds, Not set

Not set, Leicester, Not set

Not set, Liverpool, Not set

Not set, London, Not set

Not set, Manchester, Not set

Not set, Middlesbrough, Not set

Not set, Northampton, Not set

Not set, Nottingham, Not set

Not set, Sheffield, Not set

Not set, Southampton, Not set

Conditions: Arrhythmia, Bradycardia, Heart Failure, Sinus Tachycardia

Learn More ›

Developing a Decision Instrument to Guide Abdominal-pelvic CT Imaging of Blunt Trauma Patients

NCT04937868

Recruiting

Unrecognized abdominal and pelvic injuries can result in catastrophic disability and death. Sporadic reports of "occult" injuries have generated concern, and physicians, fearing that they may miss such an injury, have adopted the practice of obtaining computed tomography on virtually all patients with significant blunt trauma. This practice exposes large numbers patients to dangerous radiation at considerable expense, while detecting injuries in a small minority of cases. Existing data suggest that a limited number of criteria can reliably identify blunt injury victims who have "no risk" of abdominal or pelvic injuries, and hence no need for computed tomography (CT), without misidentifying any injured patient. It is estimated that nationwide implementation of such criteria could result in an annual reduction in radiographic charges of $75 million, and a significant decrease in radiation exposure and radiation induced malignancies. This study seeks to determine whether "low risk" criteria can reliably identify patients who have sustained significant abdominal or pelvic injuries and safely decrease CT imaging of blunt trauma patients. This goal will be accomplished in the following manner: All blunt trauma victims undergoing computed tomography of the abdomen/pelvis in the emergency department will undergo routine clinical evaluations prior to radiographic imaging. Based on these examinations, the presence or absence of specific clinical findings (i.e. abdominal/pelvic/flank pain, abdominal/pelvic/flank tenderness, bruising abrasions, distention, hip pain, hematuria, hypotension, tachycardia, low or falling hematocrit, intoxication, altered sensorium, distracting injury, positive FAST imaging, dangerous mechanism, abnormal x-ray imaging) will be recorded for each patient, as will the presence or absence of abdominal or pelvic injuries. The clinical findings will serve as potential imaging criteria. At the completion of the derivation portion of the study the criteria will be examined to find a subset that predicts injury with high sensitivity, while simultaneously excluding injury, and hence the need for imaging, in the remaining patients. These criteria will then be confirmed in a separate validation phase of the study. The criteria will be considered to be reliable if the lower statistical confidence limit for the measured sensitivity exceeds 98.0%. Potential reductions in CT imaging will be estimated by determining the proportion of "low-risk" patients that do not have significant abdominal or pelvic injuries. Read Less

Gender:

ALL

Ages:

All

Trial Updated:

12/23/2024

Locations: Ronald Reagan Hospital, Los Angeles, California

Conditions: Abdominal Injury, Pelvic Fracture, Genital Hemorrhage, Lumbar Spine Injury, Hip Injuries, Liver Injury, Spleen Injury, Renal Injury, Diaphragm Injury, Aortic Rupture, Aortic Dissection, Bowel Disease, Vascular System Injuries, Sacral Fracture

Learn More ›

Optimizing an Online Behavioral Weight Loss Intervention and Novel Culturally Tailored Components for Sexual Minority Women

NCT05775497

Recruiting

Obesity disproportionately impacts sexual minority women. Behavioral weight loss programs are the gold standard treatment for mild to moderate obesity. The investigators have developed an online behavioral weight loss program that is effective, low-cost, and highly scalable. However, existing research suggests that tailoring treatment to address 3 well-established weight loss barriers in sexual minority women will be critical for maximizing the relevance and efficacy of behavioral weight loss for this group. In the Preparation Phase of this K23, the investigators developed 3 novel treatment components targeting sexual minority women's weight loss barriers (i.e., minority stress, low social support, and negative body image), the investigators piloted the program among sexual minority women of higher weight, and the investigators conducted individual qualitative interviews to elicit feedback on the intervention's acceptability, cultural relevance, usability, and feasibility, and this feedback was used to refine the program. In the Optimization Phase of this K23 (the current phase), 88 women will receive 12 weeks of Rx Weight Loss and will be randomized to receive 0-3 tailored components in a full factorial design with 23 (8) distinct combinations of components. Novel components that increase mean weight loss (by ≥2%) or the proportion of women achieving clinically meaningful weight loss (by ≥10%) at 6 months will be retained in a finalized obesity treatment package that the investigators will evaluate in a future randomized controlled trial (RCT) (Evaluation Phase). The aims of this study are to: Aim 2A (Optimization): Use a factorial experiment to determine how 3 novel components impact mean weight loss and the proportion of women achieving a 5+% weight loss at 6 months. Aim 2B (Mediation): Clarify how tailored components impact weight loss by testing hypothesized mechanisms of action (i.e., coping with stress, perceived social support, weight and shape concerns). This project will tailor and optimize an evidence-based online behavioral obesity treatment to enhance weight loss outcomes in sexual minority women. Read Less

Gender:

FEMALE

Ages:

Between 18 years and 70 years

Trial Updated:

12/23/2024

Locations: Weight Control and Diabetes Research Center, Providence, Rhode Island

Conditions: Obesity

Learn More ›

Radioligand Therapy After PSMA PET Guided External Beam Radiotherapy for Treating Post-Prostatectomy Patients with Biochemically Recurrent Prostate Cancer

NCT06105918

Recruiting

This phase I trial tests the safety, side effects and best dose of radioligand therapy (lutetium Lu 177 PSMA-10.1 \[177Lu-rhPSMA-10.1\]) after prostate specific membrane antigen (PSMA) positron emission tomography (PET)-guided external beam radiotherapy in treating post-prostatectomy patients with prostate cancer that has come back after a period of improvement (recurrent). In this study, radioligand therapy is a radioactive drug called 177Lu-rhPSMA-10.1. It works by binding to PSMA-expressing p... Read More

Gender:

MALE

Ages:

18 years and above

Trial Updated:

12/23/2024

Locations: Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia

Conditions: Biochemically Recurrent Prostate Carcinoma, Prostate Adenocarcinoma

Learn More ›

Taste Alterations Study

NCT06669416

Recruiting

The main questions it aims to answer are: 1. Does completing a standard assessment increase the detection of chemotherapy induced taste changes compared with usual care (no assessment)? What TA are experienced? Are there any patterns in TA symptom occurrence based on age, sex, race/ethnicity, cancer type, chemotherapy agent, etc. 2. Do patients take action to deal with the TA? What strategies are used? Do patients in the intervention group use the assessments to select interventions? 3. Do the... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/23/2024

Locations: Advocate Illinois Masonic Medical Center, Chicago, Illinois

Conditions: Chemotherapy Side Effects, Taste, Altered

Learn More ›

ABL001 + Dasatinib + Prednisone + Blinatumomab in BCR-ABL+ B-ALL or CML

NCT03595917

Recruiting

This research study is evaluating a drug called ABL001 taken in combination with dasatinib (Sprycel®) and prednisone (a steroid) as a possible treatment for B-cell Acute Lymphoblastic Leukemia that is BCR-ABL positive (BCR-ABL+ B-ALL) or Chronic Myeloid Leukemia (CML) in lymphoid blast crisis. BCR-ABL+ B-ALL is also called Philadelphia chromosome positive Acute Lymphoblastic Leukemia (Ph+ ALL). It is expected that 40-65 people will take part in this research study. * ABL001 * Dasatinib (Spryce... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/23/2024

Locations: University of Chicago Comprehensive Cancer Center, Chicago, Illinois +3 locations

Conditions: B-cell Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia (CML) in Lymphoid Blast Crisis, Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia Ph+ ALL

Learn More ›

Lenvatinib for the Treatment of Recurrent Hepatocellular Carcinoma After Liver Transplant

NCT05103904

Recruiting

This phase II trial evaluates lenvatinib for the treatment of hepatocellular carcinoma (HCC) that has come back (recurrent) after a liver transplant. HCC is a cancer of the liver and is the second leading cause of cancer-related deaths in the world. Liver transplantation is a potentially curative treatment option for HCC, however, up to 20% of patients develop recurrent disease after liver transplantation and prognosis remains poor. Lenvatinib may stop the growth of tumor cells by blocking some... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/23/2024

Locations: University of Alabama at Birmingham, Birmingham, Alabama +2 locations

Conditions: Recurrent Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8, Stage IIIA Hepatocellular Carcinoma AJCC v8, Stage IIIB Hepatocellular Carcinoma AJCC v8, Stage IV Hepatocellular Carcinoma AJCC v8, Stage IVA Hepatocellular Carcinoma AJCC v8, Stage IVB Hepatocellular Carcinoma AJCC v8, Unresectable Hepatocellular Carcinoma

Learn More ›

Infrared Images for Spinal Cord Stimulation in Complex Regional Pain Syndrome Patients

NCT05777889

Recruiting

The goal of this observational study is to compare thermal camera Forward Looking InfraRed (FLIR) images before and after spinal cord stimulation to evaluate the difference in sympathetic activity of the affected limb in patients with complex regional pain syndrome (CRPS). The main questions it aims to answer are: Question 1: Can Infrared (FLIR) imaging be used to monitor the sympatholytic activity caused by Spinal Cord Stimulation (SCS) in patients with CRPS? Question 2: Is there any correlat... Read More

Gender:

ALL

Ages:

Between 18 years and 85 years

Trial Updated:

12/23/2024

Locations: Hospital for Special Surgery, New York, New York

Conditions: Complex Regional Pain Syndromes

Learn More ›

VasoStar Vibrational Guidewire System to Facilitate Crossing Coronary Artery Chronic Total Occlusions

NCT06193954

Recruiting

The goal of this project is to provide an improvement in wire performance to expedite crossing difficult lesions in the coronary vasculature.

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/23/2024

Locations: Emory University, Atlanta, Georgia +1 locations

Conditions: Chronic Total Occlusion of Coronary Artery, Chronic Angina

Learn More ›

Conduit Cages and Fibergraft BG Putty

NCT06704919

Recruiting

The Conduit cages are intended to restore the intervertebral height and to facilitate the intervertebral body fusion in the cervical and lumbar spine in skeletally mature patients with degenerative disc disease and instabilities at one or more levels of the spine. The Fibergraft Bioactive Glass (BG) is engineered to mimic the body's natural bone healing process. While previous studies have described the use of conduit cages in interbody fixation procedures, these studies did not specifically stu... Read More

Gender:

ALL

Ages:

18 years and above

Trial Updated:

12/23/2024

Locations: University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania

Conditions: Degenerative Disc Disease, Herniated Disc

Learn More ›